Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 4, 2005, Pages 981-987

  Gorelik, Elieser ^a   Landsittel, Douglas P ^a   Marrangoni, Adele M ^a   Modugno, Francesmary ^a   Velikokhatnaya, Lyudmila ^a   Winans, Matthew T ^a   Bigbee, William L ^a   Herberman, Ronald B ^a   Lokshin, Anna E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; OVARY CANCER; PELVIS TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 16444368172     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0404     Document Type: Article

References (62)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
2. Jacobs I. Overview - progress in screening for ovarian cancer. In: Sharp F, Berek J, Bast R, editors. Ovarian cancer 5. Oxford: Isis Medical Media; 1998.
3. Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology (Huntingt) 2000;14:1601-7; discussion 1608:1613-6.
4. Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematol Oncol Clin North Am 2003 Aug;17:989-1005; ix.
5. Menon U, Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002 Aug;16:469-82.
6. Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003 Apr;21:378-85.
7. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998 Oct-Dec;13:179-87.
8. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989 Jan;4:1-12.
9. Cohen L, Fishman DA. Ultrasound and ovarian cancer. Cancer Treat Res 2002;107:119-32.
10. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
11. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS. Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 2003 Dec 9;100:14666-71.
12. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003 Oct 14;100: 12343-8.
13. Vlahou A, Schorge JO, Gregory BW, Coleman RL. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol 2003;2003:308-14.
14. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003 May 15;21:200-5.
15. Liles WC, Van Voorhis WC. Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995 Dec;172:1573-80.
16. Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 1999 Mar;6:93-107.
17. Foti E, Ferrandina G, Martucci R, et al. IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology 1999 Oct;57:211-5.
18. Gadducci A, Ferdeghini M, Castellani C, et al. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol Oncol 1995 Aug;58:184-8.
19. Gadducci A, Ferdeghini M, Fanucchi A, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res 1999;19:1401-5.
20. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41.
21. Suzuki M, Kobayashi H, Ohwada M, Terao T, Sato I. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary. Gynecol Oncol 1998 Jan;68:35-7.
22. Muller L, Pawelec G. Cytokines and antitumor immunity. Technol Cancer Res Treat 2003 Jun;2:183-94.
23. Sonoda T, Kobayashi H, Kaku T, Hirakawa T, Nakano H. Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines. Cancer Lett 2003 Jul 10;196:229-37.
24. Lidor YJ, Xu FJ, Martinez-Maza O, et al. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 1993 Aug;207:332-9.
25. Di Blasio AM, Carniti C, Vigano P, Vignali M. Basic fibroblast growth factor and ovarian cancer. J Steroid Biochem Mol Biol 1995;53:375-9.
26. Versnel MA, Haarbrink M, Langerak AW, et al. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet 1994;73:60-4.
27. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995 May;95:2391-6.
28. Savarese TM, Mitchell K, McQuain C, et al. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 2001 Jan 10;162:105-15.
29. Glezerman M, Mazot M, Maymon E, et al. Tumor necrosis factor-α and interleukin-6 are differently expressed by fresh human cancerous ovarian tissue and primary cell lines. Eur Cytokine Netw 1998 Jun;9:171-9.
30. Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995 Nov 15;76:2092-6.
31. Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59:111-6.
32. Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti P. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl 1991;207:19-24.
33. Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992 Mar;79:434-40.
34. Mills GB, Bast RC Jr, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001 Oct 3;93:1437-9.
35. Panza N, Pacilio G, Campanella L, et al. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and β-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma. Cancer 1988 Jan 1;61:76-83.
36. Peters-Engl C, Medl M, Ogris E, Leodolter S. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Anticancer Res 1995 Nov-Dec;15:2727-30.
37. Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002 Aug;187:385-92.
38. Tholander B, Taube A, Lindgren A, et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol 1990 Oct;39:16-25.
39. Hogdall EV, Hogdall CK, Tingulstad S, et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 2000 Nov 20;89:519-23.
40. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000 Sep 21;243:243-55.
41. Brieman LFJ, Olshen RA, Stone CJ. Classification and regression trees. Monterey: Wadsworth and Brooks/Cole; 1984.
42. Venables W, Ripley BD. Modern applied statistics with S-Plus. New York: Springer-Verlag; 1997.
43. Efron B, Tibshirani R, Storey J, Tusher V. Empirical Bayes analysis of a microarray experiment. J Am Stat Assoc 2001;96:1151-60.
44. Tibshirani R, Efron B. Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol 2002;1.
45. Nedvidkova J, Nemec J, Stolba P, Vavrejnova V, Bednar J. Epidermal growth factor (EGF) in serum of patients with differentiated carcinoma of thyroids. Neoplasma 1992;39:1-20.
46. Lev-Ran A, Hwang DL, Ahmad B, Bixby H. Immunoreactive epidermal growth factor in serum, plasma, platelets, and urine in patients on chronic dialysis. Nephron 1991;57:164-6.
47. Hefler L, Tempfer C, Heinze G, et al. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 1999 Nov;81:855-9.
48. Mayerhofer K, Bodner K, Bodner-Adler B, et al. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer 2001;91:388-93.
49. Matsubara K, Ochi H, Kitagawa H, Yamanaka K, Kusanagi Y, Ito M. Concentrations of serum granulocyte-colony-stimulating factor in normal pregnancy and preeclampsia. Hypertens Pregnancy 1999;18:95-106.
50. Bux J, Hofmann C, Welte K. Serum G-CSF levels are not increased in patients with antibody-induced neutropenia unless they are suffering from infectious diseases. Br J Haematol 1999 Jun;105:616-7.
51. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997 Jul;66:27-30.
52. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998 Jun;69:248-52.
53. Bahner D, Klucke C, Kitze B, et al. Interferon-β-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients. Neurosci Lett 2002 Jun 28;326:125-8.
54. Baron AT, Lafky JM, Boardman CH, et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1999;8:129-37.
55. Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002;107:247-58.
56. Pack SD, Alper OM, Stromberg K, et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 2004 Feb 1;64:789-94.
57. Gorelik E, Edwards RP, Feng X, et al. IL-12 receptor-mediated up-regulation of FasL in human ovarian carcinoma cells. Int J Cancer 2004 Nov 20;112:620-7.
58. Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 2002 Nov 1;95:1886-93.
59. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002 Apr 3;287:1671-9.
60. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001 Oct 3;93:1458-64.
61. Rosenthal A, Jacobs I. Ovarian cancer screening. Semin Oncol 1998;25:315-25.
62. van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001 Dec 1;92:2837-44.